Form 4: Gilead CEO Daniel O'Day Executes Planned Stock Sale

Gilead Sciences Chairman and CEO Daniel O'Day sold 10,000 shares of common stock under a pre-established Rule 10b5-1 trading plan.

Summary

• Chairman and CEO Daniel O'Day sold a total of 10,000 shares of Gilead Sciences common stock on April 28, 2026.
• The sales were executed in two tranches: 6,950 shares at an average price of $128.7877 and 3,050 shares at an average price of $130.0111.
• Following these transactions, O'Day retains beneficial ownership of 632,567 shares of Gilead common stock.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on February 28, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; the sale is a routine, pre-planned divestment that does not reflect a change in the company's fundamental health or management's confidence.

Positives

• The sale was executed under a pre-planned Rule 10b5-1 program, which is a standard mechanism for executives to sell stock without triggering insider trading concerns.

Negatives

• The transaction represents a reduction in the CEO's direct equity stake in the company.

Risks

• Continued divestment by top leadership can sometimes be perceived negatively by retail investors, though this was a scheduled sale.

Future Outlook

No forward-looking guidance regarding company operations was provided in this filing, as it is a standard disclosure of insider transaction activity.

Industry Context

StockSavvy.ai notes that executive stock sales under Rule 10b5-1 plans are routine corporate governance events and generally do not signal a change in company strategy or outlook, but rather reflect personal financial planning by the executive.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for C-suite executives at large-cap pharmaceutical companies like Pfizer, Merck, and Amgen to manage equity holdings while maintaining regulatory compliance.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned and represents a small fraction of the CEO's total holdings.

Next Steps

• No further actions required by the reporting person regarding this specific transaction.

Key Dates

Keywords

Gilead Sciences, GILD, Insider Trading, Form 4, Daniel O'Day, Executive Compensation